LV13024B - Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors - Google Patents

Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors Download PDF

Info

Publication number
LV13024B
LV13024B LVP-03-16A LV030016A LV13024B LV 13024 B LV13024 B LV 13024B LV 030016 A LV030016 A LV 030016A LV 13024 B LV13024 B LV 13024B
Authority
LV
Latvia
Prior art keywords
naphthyridin
dihydrobenzo
group
substituted
trifluoromethyl
Prior art date
Application number
LVP-03-16A
Other languages
English (en)
Latvian (lv)
Inventor
James D Rodgers
Haisheng Wang
Mona Patel
Argyrios Arvanitis
Anthony J Cocuzza
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LV13024B publication Critical patent/LV13024B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LVP-03-16A 2000-07-20 2003-02-18 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors LV13024B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21953200P 2000-07-20 2000-07-20
US28485601P 2001-04-19 2001-04-19

Publications (1)

Publication Number Publication Date
LV13024B true LV13024B (en) 2003-10-20

Family

ID=26913986

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-03-16A LV13024B (en) 2000-07-20 2003-02-18 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors

Country Status (23)

Country Link
US (1) US6596729B2 (pl)
EP (1) EP1303515A2 (pl)
JP (1) JP2004532793A (pl)
KR (1) KR20030065454A (pl)
CN (1) CN1464878A (pl)
AR (1) AR031861A1 (pl)
AU (1) AU2001280641A1 (pl)
BG (1) BG107439A (pl)
BR (1) BR0112606A (pl)
CA (1) CA2418194A1 (pl)
EE (1) EE200300027A (pl)
HU (1) HUP0302862A2 (pl)
IL (1) IL153683A0 (pl)
IS (1) IS6690A (pl)
LT (1) LT2003003A (pl)
LV (1) LV13024B (pl)
MX (1) MXPA03000434A (pl)
NO (1) NO20030248L (pl)
PL (1) PL365958A1 (pl)
SI (1) SI21139A (pl)
SK (1) SK392003A3 (pl)
WO (1) WO2002008226A2 (pl)
YU (1) YU3203A (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
JP4822707B2 (ja) * 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 4−[[4−[[4−(2−シアノエテニル)−2,6−ジメチルフェニル]アミノ]−2−ピリミジニル]アミノ]ベンゾニトリルの製造方法
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
TW200607503A (en) 2004-05-17 2006-03-01 Tibotec Pharm Ltd 1-heterocyclyl-1, 5-dihydro-pyrido[3, 2-b]indol-2-ones

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700673A (en) * 1971-02-12 1972-10-24 Morton Norwich Products Inc 3-4-dihydrobenzo(b) (1,7)naphthyridin-1(2h)-ones
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
IL102764A0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
AU1046895A (en) 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
DE4344452A1 (de) 1993-12-24 1995-06-29 Hoechst Ag Aza-4-iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
ATE248826T1 (de) 1996-10-02 2003-09-15 Bristol Myers Squibb Pharma Co 4,4-disubstituierte 1,4-dihydro-2h-3,1-benzoxazin-2-one die anwendbar sind als hiv- reverstranskriptase-inhibitoren, zwischenprodukte und verfahren zu ihrer herstellung
HRP980143A2 (en) 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
US6593337B1 (en) 1999-10-19 2003-07-15 Bristol-Myers Squibb Pharma Company Tricyclic compounds useful as HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
MXPA03000434A (es) 2003-06-24
JP2004532793A (ja) 2004-10-28
IL153683A0 (en) 2003-07-06
YU3203A (sh) 2006-01-16
US6596729B2 (en) 2003-07-22
NO20030248L (no) 2003-03-17
HUP0302862A2 (hu) 2003-12-29
IS6690A (is) 2003-01-17
AU2001280641A1 (en) 2002-02-05
PL365958A1 (pl) 2005-01-24
BG107439A (bg) 2003-09-30
WO2002008226A3 (en) 2002-06-20
KR20030065454A (ko) 2003-08-06
US20020107261A1 (en) 2002-08-08
AR031861A1 (es) 2003-10-08
CN1464878A (zh) 2003-12-31
SI21139A (sl) 2003-08-31
WO2002008226A2 (en) 2002-01-31
CA2418194A1 (en) 2002-01-31
BR0112606A (pt) 2004-06-29
EE200300027A (et) 2004-10-15
NO20030248D0 (no) 2003-01-17
EP1303515A2 (en) 2003-04-23
LT2003003A (en) 2003-11-25
SK392003A3 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
WO2021155716A1 (zh) 吡啶并嘧啶酮类化合物及其应用
AU773309B2 (en) Tricyclic compounds useful as HIV reverse transcriptase inhibitors
US6844340B2 (en) Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
US6596729B2 (en) Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US6809109B2 (en) 2, 4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
US6969721B2 (en) Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US6204262B1 (en) 1,3-Benzodiazepin-2-ones and 1,3-Benzoxazepin-2-ones useful as HIV reverse transcriptase inhibitors
AU2003203047A1 (en) Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
ZA200203131B (en) Condensed naphthyridines as HIV reverse transcriptase inhibitors.
WO2000073284A2 (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
CA2330110A1 (en) 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors